CONTEXT: Whether testosterone (Te) depletion in aging men reflects deficits in the testis, hypothalamus, and/or pituitary gland is unknown. OBJECTIVE: Our objective was to quantify the impact of age on gonadal Te secretion driven by amplitude-varying pulses of recombinant human LH (rhLH) in the absence of confounding by endogenous hypothalamo-pituitary signals. DESIGN: This was a double-blind, placebo-controlled study. SETTING: The setting was an academic medical center. SUBJECTS:Fifteen healthy community-dwelling men ages 22-78 yr were included in the study. INTERVENTION: Saline or four separate rhLH doses were each infused twice iv in randomized order as one pulse every 2 h over 20 h to stimulate Te secretion, after LH secretion was suppressed by a GnRH-receptor antagonist, ganirelix. MAIN OUTCOME: LH and Te concentrations were determined in blood samples collected every 5 min. Maximal and minimal (as well as mean) Te responses were regressed linearly on age to reflect LH peak and nadir (and average) effects, respectively. RESULTS: The ganirelix/rhLH paradigm yielded serum LH concentrations of 4.6 +/- 0.22 IU/liter (normal range 1-9). By regression analysis, age was associated with declines in rhLH pulse-stimulated peak and nadir (and mean) concentrations of total Te (P = 0.0068), bioavailable Te (P = 0.0096), and free Te (P = 0.013), as well as lower Te/LH concentration ratios (P < 0.005). Deconvolution analysis suggested that the half-life of infused LH increases by 12%/decade (P = 0.044; R(2) = 0.28). CONCLUSIONS: Infusion of amplitude-varying pulses of rhLH during gonadal-axis suppression in healthy men unmasks prominent age-related deficits in stimulated total (39%), bioavailable (66%), and free (63%) Te concentrations, and a smaller age-associated increase in LH half-life. These data suggest that age-associated factors reduce the efficacy of LH pulses.
RCT Entities:
CONTEXT: Whether testosterone (Te) depletion in aging men reflects deficits in the testis, hypothalamus, and/or pituitary gland is unknown. OBJECTIVE: Our objective was to quantify the impact of age on gonadal Te secretion driven by amplitude-varying pulses of recombinant humanLH (rhLH) in the absence of confounding by endogenous hypothalamo-pituitary signals. DESIGN: This was a double-blind, placebo-controlled study. SETTING: The setting was an academic medical center. SUBJECTS: Fifteen healthy community-dwelling men ages 22-78 yr were included in the study. INTERVENTION: Saline or four separate rhLH doses were each infused twice iv in randomized order as one pulse every 2 h over 20 h to stimulate Te secretion, after LH secretion was suppressed by a GnRH-receptor antagonist, ganirelix. MAIN OUTCOME: LH and Te concentrations were determined in blood samples collected every 5 min. Maximal and minimal (as well as mean) Te responses were regressed linearly on age to reflect LH peak and nadir (and average) effects, respectively. RESULTS: The ganirelix/rhLH paradigm yielded serum LH concentrations of 4.6 +/- 0.22 IU/liter (normal range 1-9). By regression analysis, age was associated with declines in rhLH pulse-stimulated peak and nadir (and mean) concentrations of total Te (P = 0.0068), bioavailable Te (P = 0.0096), and free Te (P = 0.013), as well as lower Te/LH concentration ratios (P < 0.005). Deconvolution analysis suggested that the half-life of infused LH increases by 12%/decade (P = 0.044; R(2) = 0.28). CONCLUSIONS: Infusion of amplitude-varying pulses of rhLH during gonadal-axis suppression in healthy men unmasks prominent age-related deficits in stimulated total (39%), bioavailable (66%), and free (63%) Te concentrations, and a smaller age-associated increase in LH half-life. These data suggest that age-associated factors reduce the efficacy of LH pulses.
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Johannes D Veldhuis; Paul Y Takahashi; Daniel M Keenan; Peter Y Liu; Kristi L Mielke; Suanne M Weist Journal: Am J Physiol Endocrinol Metab Date: 2010-08-03 Impact factor: 4.310
Authors: Johannes D Veldhuis; Olga P Bondar; Roy B Dyer; Sergey A Trushin; Eric W Klee; Ravinder J Singh; George G Klee Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Peter Y Liu; Paul Y Takahashi; Pamela D Roebuck; Joy N Bailey; Daniel M Keenan; Johannes D Veldhuis Journal: J Clin Endocrinol Metab Date: 2009-07-07 Impact factor: 5.958
Authors: Johannes D Veldhuis; Peter Y Liu; Paul Y Takahashi; Daniel M Keenan Journal: Am J Physiol Endocrinol Metab Date: 2012-07-17 Impact factor: 4.310
Authors: Johannes D Veldhuis; Daniel M Keenan; Joy N Bailey; Adenborduin Adeniji; John M Miles; Remberto Paulo; Mihaela Cosma; Cacia Soares-Welch Journal: J Clin Endocrinol Metab Date: 2008-11-04 Impact factor: 5.958